GLP-1 Side Effects: What's Common, What's Concerning, and What to Do Next

This article works through the safety picture the way a careful clinician would. What's frequently reported, what tends to happen during dose escalation, what warrants a call to your care team, and what warrants urgent evaluation. Where numbers exist, they're attached to the specific product, dose, and trial population they came from, because a rate that applies to semaglutide 2.4 mg is not automatically a rate for tirzepatide, and neither is automatically a rate for a personalized preparation.

A note on scope. HealthiCare offers personalized semaglutide and personalized tirzepatide. These are different from the approved brand-name products, and the FDA has not reviewed them for safety, effectiveness, or quality. When trial rates from Wegovy or Zepbound are cited below, they describe those approved products at the doses studied, not a guarantee of what any individual will experience on any preparation.

The digestive symptoms most people are asking about

Gastrointestinal side effects are the category most commonly reported with both medications, and they're the reason most people search for information in the first place.

For semaglutide 2.4 mg studied for weight management in the STEP 1–3 trials, pooled rates were:

• Nausea:43.9% (vs. 16.1% placebo)
• Diarrhea:29.7% (vs. 15.9%)
• Vomiting:24.5% (vs. 6.3%)
• Constipation:24.2% (vs. 11.1%)

Source: Wegovy prescribing information and the STEP 1–3 pooled analysis.

For tirzepatide studied for weight reduction, the Zepbound label reports by 5 / 10 / 15 mg dose:

• Nausea:25% / 29% / 28% (vs. 8% placebo)
• Diarrhea:19% / 21% / 23% (vs. 8%)
• Vomiting:8% / 11% / 13% (vs. 2%)
• Constipation:17% / 14% / 11% (vs. 5%)

Two things worth noticing. First, tirzepatide's reported nausea and vomiting rates in these trials sit below semaglutide 2.4 mg's, but the trials enrolled different populations under different designs, and there is no clean head-to-head safety trial that establishes one medication as reliably easier to tolerate than the other. Second, "common" does not mean "harmless," and a rate is not a forecast for any one person.

How long symptoms tend to last

The STEP pooled analysis found the majority of semaglutide GI events (98.1%) were mild-to-moderate and 99.5% were non-serious. Median duration of an individual event was 8 days for nausea, 3 days for diarrhea, 2 days for vomiting, and 47 days for constipation. Prevalence peaked around week 20 during dose escalation and declined afterward. About 4.3% of participants discontinued because of GI events. (Source.)

The Zepbound label similarly notes that the majority of nausea, vomiting, and diarrhea events occurred during dose escalation and decreased over time, without specifying a universal week-by-week resolution schedule.

The practical takeaway. Nausea, diarrhea, and vomiting tend to be worst around dose increases and tend to shorten as you stabilize. Constipation follows a different pattern in the pooled data, with a much longer median event duration.

What to expect around a scheduled dose increase

Because both product labels and the STEP pooled data show GI symptoms concentrated during escalation, it's reasonable to expect that symptoms you thought were behind you may return or intensify in the days after a step up. That is a moment to contact your prescribing team rather than adjust the dose on your own. Depending on how you're tolerating the step, the clinician may discuss pacing options such as holding the current dose longer before advancing. None of that guarantees symptoms will resolve, but the decision belongs with the prescriber, not with a solo change at home.

Reasonable things to try for mild symptoms, and when to stop trying them

For nausea at a stable, tolerable dose, smaller meals, avoiding high-fat and heavily spiced foods, and staying hydrated are the low-risk moves most clinicians suggest. For constipation, general practices like adequate fluid, fiber, and regular movement are reasonable starting points. The Wegovy and Zepbound labels specifically emphasize hydration because volume depletion from GI losses can lead to acute kidney injury, which is a reason not to power through persistent vomiting or diarrhea.

Conservative steps stop being the right answer when symptoms are persistent, when you can't keep fluids down, when pain enters the picture, or when you're losing ground rather than adjusting. At that point the next move is your care team, not another tweak at the kitchen table. For a deeper walkthrough of nausea and early-fullness management, see managing nausea and fullness on GLP-1.

When symptoms cross from expected to concerning

Contact your prescribing team promptly, rather than waiting it out, if any of these apply:

• Nausea, vomiting, or diarrhea that persist, especially if you can't keep fluids down. This is where volume depletion and acute kidney injury enter the picture, per both product labels.
• Severe, persistent abdominal pain, particularly upper abdominal pain that may radiate to the back, with or without vomiting. Acute pancreatitis has been reported with both medications. Per the Wegovy and Zepbound labels, the drug should be stopped and prompt evaluation obtained if pancreatitis is suspected.
• Right-upper-abdominal pain, fever, jaundice, or clay-colored stools. Gallbladder disease, including cholecystitis and cholelithiasis, is a recognized warning in both product labels and requires clinical evaluation rather than self-diagnosis.
• Signs of a serious allergic reaction, such as swelling of the face, lips, tongue, or throat, or difficulty breathing or swallowing. Known serious hypersensitivity to the medication is a contraindication.

Do not stop, hold, restart, or change your dose on your own outside these label-directed situations. Contact your prescriber.

The boxed warning, in plain language

Both Wegovy and Zepbound carry a boxed warning based on thyroid C-cell tumors observed in rodent studies. Human relevance is unknown. Because of this signal, both products are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is a candidacy question worth raising before your first dose, not after.

The boxed warning is not the whole safety profile. Pancreatitis, gallbladder disease, kidney injury from volume depletion, and serious hypersensitivity all sit alongside it in the labels.

Who should not take GLP-1 medications?

Some people should not take certain GLP-1 medications. Others need extra planning or monitoring before starting or restarting. Tell your clinician if any of these apply:

• Personal or family history of MTC or MEN 2. Contraindicated per both labels.
• Type 2 diabetes on insulin or a sulfonylurea (or similar insulin secretagogue). GLP-1 therapy increases hypoglycemia risk in these combinations. Make sure the clinician prescribing your GLP-1 knows about the combination. Hypoglycemia can still occur in other contexts, but the risk is highest with these medication combinations.
• Type 2 diabetes with a history of diabetic retinopathy. Both labels note that rapid glucose improvement can temporarily worsen retinopathy in some patients. This is population-specific, not a general eye-risk warning.
• Pregnancy, planning pregnancy, or oral contraception. Weight-loss use during pregnancy is not appropriate. The Wegovy label advises discontinuing semaglutide at least two months before a planned pregnancy given its long half-life. Tirzepatide can reduce oral-contraceptive exposure after initiation and each dose escalation, and the Zepbound label addresses backup or non-oral contraception during those windows.
• Planned surgery, endoscopy, or any procedure with anesthesia or deep sedation. Both labels note pulmonary aspiration has been reported despite reported fasting. Disclose GLP-1 use to your procedure team in advance and follow their instructions. There is no universal stop interval to apply on your own.

Two long-running questions the current evidence answers only partly

Hair shedding

In Wegovy trials, hair loss was reported in 3% of participants vs. 1% on placebo. In Zepbound trials, rates were 5% / 4% / 5% across doses, with a striking sex difference of 7.1% in women vs. 0.5% in men, and the label associates events with weight reduction. A 2026 systematic review confirms the association but leaves the mechanism unresolved. The often-repeated claim that this is purely telogen effluvium from rapid weight loss goes further than the evidence supports. It's a real signal, and the exact contribution of the medication versus the weight loss itself isn't settled.

Lean mass

A 2026 meta-analysis of 20 randomized trials (15,782 participants) reported that lean mass accounted for 35.2% of total weight lost with semaglutide and 25.4% with tirzepatide, compared with 26.2% for lifestyle interventions alone. So the proportion of lean-mass loss on GLP-1 therapy is real, but it isn't uniquely a GLP-1 phenomenon. Substantial weight loss by most methods involves some lean-mass loss. Lean mass on a body-composition scan is also not identical to skeletal muscle, and the proportion varies by measurement method.

Resistance training and adequate protein intake are reasonable general practices for anyone losing weight, and the meta-analysis findings are consistent with a benefit from lifestyle plus resistance training. A GLP-1-specific trial designed to quantify how much preservation resistance training and protein deliver is currently a published protocol, not a completed result, so specific protein targets and preservation magnitudes shouldn't be presented as settled. For practical guidance, see strength training on GLP-1 and getting enough protein when your appetite is low.

Common claims that don't hold up against the labels

A few statements circulate widely enough that it's worth being explicit about where they part company with the evidence.

• "Injecting at night reduces nausea because the peak hits during sleep." The pharmacokinetics don't support this. Semaglutide reaches maximum concentration 1–3 days after a dose. Tirzepatide's median time to maximum concentration is about 24 hours (range 8–72). Both labels allow weekly dosing at any time of day. Choose a day and time you'll remember. For more on timing, see the best time to take GLP-1.
• "Fatigue is caused by cutting calories too fast." Fatigue is listed among common reactions in both labels, but the labels do not establish a single cause. Persistent or severe fatigue is worth raising with your care team rather than self-diagnosing.
• "The FDA is actively investigating a suicidality signal." As of the FDA's January 13, 2026 communication, its evaluation did not identify an increased risk, and the agency requested removal of the suicidal-behavior-and-ideation warning. Some product labels may not yet reflect this change.